Strategic Family Wealth Counselors L.L.C. Increases Holdings in Johnson & Johnson $JNJ

Strategic Family Wealth Counselors L.L.C. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 82.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,868 shares of the company’s stock after purchasing an additional 3,102 shares during the period. Strategic Family Wealth Counselors L.L.C.’s holdings in Johnson & Johnson were worth $1,499,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Abich Financial Wealth Management LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $26,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $26,000. DecisionPoint Financial LLC boosted its position in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares in the last quarter. Family CFO Inc bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC boosted its position in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform” and lifted its price target to $265 from $252, citing accelerating growth prospects from new drug launches and stronger oncology and immunology franchises. Johnson & Johnson upgraded at Leerink on growth prospects
• Positive Sentiment: Analysts highlighted J&J’s pipeline momentum, including Tremfya and newly approved Icotyde as key drivers for immunology growth as Stelara faces biosimilar pressure, reinforcing the company’s post-Stelara strategy. Tremfya, Icotyde Lead J&J’s Post-Stelara Immunology Strategy
• Positive Sentiment: J&J also announced the global launch of the Shockwave C2 Aero Coronary IVL Catheter, adding another product launch that supports its cardiovascular growth story. Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
• Neutral Sentiment: J&J remains in focus as a defensive, high-quality name with one of the market’s strongest credit ratings, which may keep income-focused investors interested but is less likely to be a near-term catalyst. The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
• Neutral Sentiment: The company also got attention in articles emphasizing its safety, dividend appeal, and retirement-portfolio status, which supports the stock’s defensive reputation rather than signaling a major fundamental change. Russell 1000 Dividend ETF Hits 125 as Johnson & Johnson Leads The Safety Test

Analysts Set New Price Targets

Several analysts have weighed in on JNJ shares. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a research report on Wednesday. HSBC boosted their price target on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Guggenheim boosted their price target on Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Finally, Argus upped their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Stock Performance

JNJ stock opened at $230.43 on Thursday. The stock’s 50 day simple moving average is $235.82 and its 200 day simple moving average is $221.47. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $554.69 billion, a PE ratio of 26.64, a price-to-earnings-growth ratio of 2.20 and a beta of 0.27. Johnson & Johnson has a 12-month low of $146.12 and a 12-month high of $251.71.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the previous year, the company earned $2.77 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is currently 60.12%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last three months. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.